CAR T-Cell Trials Boast Promising Results – The Scientist
The Scientist |
CAR T-Cell Trials Boast Promising Results
The Scientist Multiple myeloma cellsWIKIMEDIA, KGHNanjing Legend Biotech’s chimeric antigen receptor T–cell (CAR T) therapy induced some level of remission within two months in 33 of 35 multiple myeloma patients in an ongoing clinical trial, according to results … Blood and bone marrow therapies grab spotlight at world’s top cancer meeting (CELG, MRK)Markets Insider Blood cancer treatment called ‘revolutionary’ after all study patients respondedWKYC-TV |
The Scientist |
CAR T-Cell Trials Boast Promising Results
The Scientist Multiple myeloma cellsWIKIMEDIA, KGHNanjing Legend Biotech’s chimeric antigen receptor T–cell (CAR T) therapy induced some level of remission within two months in 33 of 35 multiple myeloma patients in an ongoing clinical trial, according to results … Blood and bone marrow therapies grab spotlight at world’s top …KFGO Blood cancer treatment called ‘revolutionary’ after all study patients respondedWKYC-TV |
CBS St. Louis |
Institute for Clinical Immuno-Oncology (ICLIO) Delivers Immunotherapy Education in the Community Setting
PR Newswire (press release) Through these initiatives, ICLIO faculty engage multidisciplinary care teams in robust discussions on the real-world challenges and complexities of delivering immunotherapy to patients in the community setting. ICLIO is an institute of the Association … CAR T-Cell Trials Boast Promising ResultsThe Scientist CAR T-cell therapy — Why it’s too soon to speculate about a ‘cure’ for multiple myelomaHealthNewsReview.org New cell therapy offers hope of a leukemia cureIndependent Online |
Xconomy |
Grab Your Ticket for What’s Hot in Cancer Immunotherapy 2017 on June 14th
Xconomy We are just a week away from “What’s Hot in Cancer Immunotherapy 2017”—and we’re offering you a chance to save $100. Join us for an afternoon of spotlight talks, fireside chats, and panel discussions that will delve into a variety of cancer … High cost of cancer drugs takes centre stage at ASCOpharmaphorum |
|
Our Annual Cancer Immunotherapy Update
Life Science Leader Magazine When we started our series, “Combination Cancer Immunotherapy — A Virtual Roundtable,” in 2014, our basic assumptions were not the consensus view. We assumed immunotherapy, now more commonly called immuno-oncology (IO), would become the … |
Genetic Literacy Project |
‘A Crack in Creation’: Jennifer Doudna’s CRISPR memoir is flawed, but convincing
Genetic Literacy Project The prospect of a memoir from Jennifer Doudna, a key player in the CRISPR story, quickens the pulse. And A Crack in Creation does indeed deliver a welcome perspective on the revolutionary genome-editing technique that puts the power of evolution into … |